Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

I am searching for a
Reset Form
placeholder image: silhouette of male physician

David R. Lynch, MD, PhD Children's Hospital of Philadelphia Provider

Professor of Neurology in Pediatrics Professor of Neurology

Dr. Lynch is employed by the Children's Hospital of Philadelphia.

Request a Callback
No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients in a medical practice setting.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.

About Dr. David R. Lynch

Recognized by Best Doctors in America 2005 - 2018

Recognized in Philadelphia Magazine's May 2002 Top Docs issue

Clinical Specialties


  • Neurology

Programs & Centers:

  • General Neurology Program

Board Certification:

  • Neurology, 1993

Clinical Expertise:

  • Ataxia
  • Neurogenetics
  • Parkinson's Disease

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Johns Hopkins University School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American Academy of Neurology, National American Neurological Association, International Australian Medical Research Council, International Cooperative Ataxia Group (CAG), National French Government Scientific Review, International Friedreich Ataxia Research Alliance, National Government, Czech Republic, International MDA, National National Ataxia Foundation, National NeuroNext, International NIH RAID Program, National NIH, National NINDS Committee on Common Data Elements, International Society for Neuroscience, National

Hospital Affiliation

Dr. Lynch is employed by the Children's Hospital of Philadelphia.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Description of Research Expertise:

NMDA receptors

glutamate, receptor

Molecular biology

Excitotoxicity is a unique pathophysiological mechanism which is involved in cerebral ischemia, secondary damage in neuronal trauma, and neuronal damage from prolonged seizures. The deleterious effects from excitotoxicity result from calcium entry through a specific glutamate receptor, the N-methyl D-aspartate (NMDA) receptor. NMDA receptor antagonists act both as neuroprotective agents against excitotoxicity and as anticonvulsants in animals, but human clinical trials with the most potent agents have been complicated by side effects including psychosis. Much evidence indicates the presence of multiple types of NMDA receptors in the brain, and evidence from our laboratory suggests that different subtypes play different roles in physiological and excitotoxic processes. If one could develop therapeutic agents which are selective for the subtypes involved in excitotoxicity, one could more readily utilize NMDA receptor antagonists for treatment of human diseases.

We use a systematic approach to examine the subtype specific physiological and pharmacological properties of NMDA receptors. NMDA receptors are created in tissue culture expression systems, and their properties are studied biochemically, pharmacologically and physiologically to correlate receptor properties in these systems with such properties in vivo. We have previously shown that different NMDA receptor subtypes have distinct pharmacologies and produce different changes in intracellular calcium. In the near future we will extend these examinations of subtype specific properties to include the modulation of other intracellular messengers such as nitric oxide and examine the effect of such properties on excitotoxicity. Combined with our studies on the pharmacological specificity of NMDA receptor subtypes, this will facilitate the development of therapeutic agents directed to those NMDA receptors which play crucial roles in excitotoxicity.

Selected Publications:

Dong, Y, Mcmillan E, Clark E, Lin H, Lynch DR: GRP75 overexpression rescues frataxin deficiency and mitochondrial phenotypes in Friedreich Ataxia cellular models Human Mol Genet 28 (10): 1594-1607,2019.

Clark, E., Schadt, K., Strawser, C., Lynch, D. R.: Identification of a Novel Missense Mutation in Friedreich’s Ataxia –FXNW168R Annals Clin Translational Neurol 6 (4): 812-816,2019.

Lynch DR, Hauser L, McCormick A, Wells M, Dong YN, McCormack S, Schadt K, Perlman S, Subramony SH, Mathews KD, Brocht A, Ball J, Perdok R, Grahn A, Vescio T, Sherman JW, Farmer JM: Randomized, Double-Blind, Placebo-Controlled Study of Interferon- γ1b in Friedreich Ataxia Annals of Clinical and Translational Neurology 6 (3): 546-553,2019.

Puligedda, R., Devi, C., Fetwehal, S, Uvaru, L, Kouiavskaia, D, Chumakov, K, Lynch, D, Prend, G, Kaushik, R., Dessain, : Capture and display of antibodies secreted by hybridoma cells enables fluorescent on-cell screening Monoclonal Antibodes 22 : 1-13,2019.

Jacobi, A. A, Halawani, S., Lynch, D.R., Lin, H: Neuronal serine racemase associates with Disrupted-In-Schizophrenia-1 and DISC1 agglomerates: Implications for schizophrenia Neurosci Lett 692: : 107-114,2019.

Marty B, Naeije G, Bourguignon M, Wens V, Jousmäki V, Lynch DR, Gaetz W, Goldman S, Hari R, Pandolfo M, De Tiège X.: Evidence for genetically determined degeneration of proprioceptive tracts in Friedreich ataxia Neurology 93 (2): e116-e124,2019.

Liwei Wenga, b, Qingqing Wanga, b, Sixiang Yuc, Xiaolu Yangc, David R. Lyncha, d, Clementina Mesarosa, b, c, Ian A. Blaira: Evaluation of Antibodies for Western Blot Analysis of Frataxin Protein Isoforms Journal of Immunological Methods : 2019.

Patel M, Schadt K, McCormick A, Isaacs C, Dong YN, Lynch DR.: Open label Pilot Study of Oral Methylprednisolone for the Treatment of Patients with Friedreich Ataxia. Muscle Nerve : 2019.

Guo, L., Wang, Q., Weng, L., Hauser, L., Strawser, C., Mesaros, Lynch, D.R., Blair, I: Characterization of a new N-terminally acetylated extra-mitochondrial isoform of frataxin in human erythrocytes Sci Reports 8 (1): 17043,2018.

Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, Snyder N, Boesch S, Chin M, Delatycki MB, Giunti P, Goldsberry A, Hoyle C, McBride MG, Nachbauer W, O'Grady M, Perlman S, Subramony SH, Wilmot GR, Zesiewicz T, Meyer C: Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia Ann Clin Transl Neurol 6 (1): 15-26,2018.

Academic Contact Info

502 Abramson Center
Children's Hospital of Philadelphia

Philadelphia, PA 19104
Phone: (215) 590-2242
Patient appointments: 800-789-7366 (PENN)

Related Links